WestEnd Advisors’s Charles River Laboratories CRL Stock Holding History

WestEnd Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454	Hold	2	–	–	﹤0.01%	348
2026 Q1	$345	Hold	2	–	–	﹤0.01%	338
2025 Q4	$399	Buy	2 +1	+100%	+$181	﹤0.01%	327
2025 Q3	$156	Sell	1 -1	-50%	-$159	﹤0.01%	381
2025 Q2	$303	Hold	2	–	–	﹤0.01%	327
2025 Q1	$301	Buy	2 +1	+100%	+$168	﹤0.01%	315
2024 Q4	$185	Hold	1	–	–	﹤0.01%	265
2024 Q3	$197	Hold	1	–	–	﹤0.01%	291
2024 Q2	$207	Hold	1	–	–	﹤0.01%	260
2024 Q1	$271	Hold	1	–	–	﹤0.01%	220
2023 Q4	$236	Hold	1	–	–	﹤0.01%	220
2023 Q3	$196	Buy	+1	New	+$205	﹤0.01%	234
2023 Q1	–	Sell	-1	Closed	-$227	–	233
2022 Q4	$218	Hold	1	–	–	﹤0.01%	220
2022 Q3	$0	Hold	1	–	–	﹤0.01%	177
2022 Q2	$213	Buy	+1	New	+$244	﹤0.01%	211

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

WestEnd Advisors's CRL Position: Q2 2026 in Review

WestEnd Advisors held its Charles River Laboratories (CRL) position steady in Q2 2026 at 2 shares worth $454. The position accounts for ﹤0.01% of the portfolio, ranked #348.

WestEnd Advisors first reported a position in CRL in Q2 2022 and has held it in 15 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

WestEnd Advisors held 2 shares of Charles River Laboratories worth $454 as of Q2 2026.
WestEnd Advisors left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #348 holding.
WestEnd Advisors first reported a position in Charles River Laboratories in Q2 2022 and has held it in 15 quarters since.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.